Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis

被引：0
|
作者：
Qin, B. [1 ]
Jiao, X. [1 ]
Liu, K. [1 ]
Zang, Y. [1 ]
机构：
[1] Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.697
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
664P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [32] EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy
    Wang, L.
    Su, S.
    Lv, X.
    Liu, Y.
    Chen, F.
    Shao, J.
    Liu, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S391 - S391
  • [33] Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
    Seki, Nobuhiko
    Natsume, Maika
    Ochiai, Ryosuke
    Haruyama, Terunobu
    Ishihara, Masashi
    Fukasawa, Yoko
    Sakamoto, Takahiko
    Tanzawa, Shigeru
    Usui, Ryo
    Honda, Takeshi
    Ota, Shuji
    Ichikawa, Yasuko
    Watanabe, Kiyotaka
    CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 91 - 97
  • [34] AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models
    Polonio-Alcala, Emma
    Porta, Rut
    Ruiz-Martinez, Santiago
    Vasquez-Dongo, Carmen
    Relat, Joana
    Bosch-Barrera, Joaquim
    Ciurana, Joaquim
    Puig, Teresa
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [35] Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
    Yi, Lilan
    Fan, Junsheng
    Qian, Ruolan
    Luo, Peng
    Zhang, Jian
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 284 - 294
  • [36] Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT
    Li, Dandan
    Zhang, Lu
    Zhou, Junhao
    Chen, Hong
    LUNG CANCER, 2016, 93 : 35 - 42
  • [37] A meta-analysis of comparing EGFR-TKI with chemotherapy as the second-line treatment of NSCLC patients with wild-type EGFR.
    Gao, Guanghui
    Ren, Shengxiang
    Li, Aiwu
    He, Yayi
    Chen, Xiaoxia
    Li, Wei
    Zhou, Fei
    Li, Shuai
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated NSCLC
    Okura, Naoko
    Taniguchi, Hirokazu
    Tanimura, Keiko
    Horinaka, Mano
    Sakai, Toshiyuki
    Tanaka, Kohei
    Kozaki, Ryohei
    Yano, Seiji
    Yamada, Tadaaki
    CANCER SCIENCE, 2021, 112 : 891 - 891
  • [39] Cigarette Smoke Extract Exposure Induces EGFR-Tki Resistance In EGFR-Mutated Nsclc Via Mediating Src Activation And Emt
    Chen, H.
    Li, D.
    Zhang, L.
    Zhou, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [40] The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials
    Tang, Xiumei
    Li, Weimin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345